MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to ...

Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the ...

Piper Sandler analyst Allison M. Bratzel raised the firm’s price target on MeiraGTx (MGTX) to $30 from $28 and keeps an Overweight rating on the ...

Lilly gains worldwide exclusive rights to MeiraGTx AAV-AIPL1 program for the treatment of Leber congenital amaurosis 4.

WASHINGTON-Syria has joined the U.S.-led mission to defeat Islamic State, U.S. officials said, after President Trump and Syrian President Ahmed al-Sharaa met at the White House on Monday. The move ...

The prolonged shutdown has taken a toll on consumer confidence and the overall economy, with consumer sentiment dropping to ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking ...

Wall Street analysts display divided opinions regarding Eli Lilly's prospects. Leerink Partners recently elevated its rating from "Market Perform" to "Outperform," simultaneously raising its price ...

MeiraGTx Holdings PLC stock grades by Barron's. View MGTX fundamental and sentiment analysis powered by MarketGrader.

In today’s ACT Brief, we look at how adaptive trial models are reshaping precision medicine, new data showing Wegovy’s impact ...